Medical / Pharmaceuticals
Releases published in the last 30 days. 
Page 1 of 2
- A New Book Encourages Patients to Take Control of Their Healthcare
- 4/8/2026 2:54:37 PM
- For many people, healthcare has become increasingly complicated. Long wait times, rising costs, and confusing insurance requirements can leave patients feeling powerless at the very moment they need clarity the most.
- Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe
- 4/8/2026 12:48:40 PM
- Johnson & Johnson announced the launch of VARIPULSE Pro in Europe following CE Mark approval, further advancing its pulsed field ablation (PFA) portfolio.
- Mila’s AI drives world’s largest study on psychedelics
- 4/8/2026 4:56:49 AM
- Psychedelics research is booming, with many research labs seeking cheaper, more effective alternative drug treatments to mental health conditions like depression and schizophrenia.
- From misdiagnosis to medical bias: Why women are living longer but not better
- 4/7/2026 4:16:16 PM
- Across the world, UN data shows, women are still less likely to be taken seriously, accurately diagnosed, or appropriately treated. From misdiagnosis to entrenched medical bias, gaps in healthcare systems continue to affect women’s health, safety and quality of life.
- AMA statement on Rx and Illicit Drug Summit
- 4/7/2026 2:15:04 PM
- Statement attributable to: Bobby Mukkamala, MD President, American Medical Association “As leaders from across medicine, pharmacy, and public health convene today at the Rx and Illicit Drug Summit, our message is clear: collaboration across care teams is essential to addressing the nation’s evolving substance use and overdose epidemic.
- Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
- 4/7/2026 11:17:25 AM
- • The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status • The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, reinforcing lunsekimig’s potential as a respiratory treatment • The exploratory VELVET phase 2b study did not meet …
- WHO calls for action: “Together for health. Stand with science.” to mark World Health Day
- 4/6/2026 12:26:46 PM
- The World Health Organization (WHO) today calls on people everywhere to renew their commitment to working together and supporting science as the twin engines driving better health, under the World Health Day 2026 theme: “Together for health.
- THMT Launches 2026 Premiere Issue
- 4/6/2026 8:30:00 AM
- The 2026 premiere issue of Telehealth and Medicine Today (THMT) is now live, marking a pivotal evolution in the journal’s leadership, editorial direction, and commitment to advancing virtual care.
- Urban health leaders renew commitment to accelerate life-saving action in cities
- 4/2/2026 12:53:10 PM
- As noncommunicable diseases and injuries continue to account for more than 80% of deaths worldwide, global urban health experts concluded the 2026 Partnership for Healthy Cities Summit in Rio de Janeiro this week with a renewed commitment to accelerate life-saving action in cities.
- Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
- 4/1/2026 12:31:42 PM
- Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease • Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the …
- Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia
- 4/1/2026 11:16:38 AM
- This announcement contains inside information CHESTNUT randomised, open-label, active-controlled trial demonstrated safety and tolerability of efzimfotase alfa in paediatric patients previously treated with Strensiq with maintenance of therapeutic benefit MULBERRY randomised, placebo-controlled trial showed efzimfotase alfa demonstrated statistically significant and …
- INLEXZO™ (gemcitabine intravesical system) Assigned Permanent Billing Code, Supporting Access for Patients with Certain Bladder Cancers
- 4/1/2026 10:56:01 AM
- Johnson & Johnson (NYSE:JNJ) today announced the permanent Healthcare Common Procedure Coding System (HCPCS) J-code for INLEXZO™ (gemcitabine intravesical system) is now in effect.
- THMT Releases 2025 Research Compendium Featuring Global Advances in Telehealth, AI, and Digital Medicine
- 3/31/2026 8:00:00 AM
- Telehealth and Medicine Today (THMT) today announced the release of its 2025 Open Access Research Compendium, featuring a comprehensive collection of peer reviewed articles alongside its expanding archive of real world research shaping telehealth, artificial intelligence (AI), and digital medicine worldwide.
- Jimini Health Raises $17M as Behavioral Health Systems Face Growing Pressure to Manage Patient AI Use with Clinical-Grade Infrastructure
- 3/31/2026 6:00:00 AM
- Jimini Health today announced $17 million in seed funding from M13, Town Hall Ventures, LionBird, Zetta Venture Partners, and OneMind, bringing total funding to more than $25 million.
- MENU - ORDER AI Becomes #1 App for GLP-1 Meal Searches on the Apple App Store in the United States
- 3/30/2026 2:28:11 PM
- MENU - ORDER AI, the AI-powered dining companion helping users choose high-protein, GLP-1 friendly meals in seconds, announced today that it has become the #1 app searched for GLP-1 meal guidance on the Apple App Store in the United States.
- Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma
- 3/30/2026 9:51:58 AM
- The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa (isatuximab) subcutaneous (SC) in combination with approved standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all currently approved indications for Sarclisa intravenous (IV) …
- BHTY Unveils 2025 Research Compendium Advancing Global Leadership in Blockchain, AI, and Digital Health
- 3/30/2026 8:00:00 AM
- Blockchain in Healthcare Today (BHTY) today announced the release of its 2025 Research Compendium, featuring all original research articles published this year alongside the complete archive of peer reviewed research since the journal’s launch.
- CMS launches model to improve care coordination for children and families
- 3/27/2026 10:01:01 AM
- The American Medical Association (AMA) welcomed a newly announced care model from the Centers for Medicare & Medicaid Services (CMS) designed to help Medicaid families better navigate and coordinate their health care.
- Activating Your Brain While Sitting Helps Reduce Dementia Risk
- 3/26/2026 11:08:15 AM
- New research distinguishing between passive and mentally active sitting in association with dementia has found that adults who engaged in extended durations of mentally passive sedentary behaviors had a higher risk of dementia.
- AMA launches nutrition education initiative
- 3/25/2026 10:52:11 AM
- The American Medical Association (AMA) is launching a nutrition education initiative to equip physicians and medical students with practical, evidence-based knowledge and tools to help patients live healthier lives.